A Study to Investigate Safety and Effectiveness of CRN09682 in Participants With SST2-Expressing NENs and Other Solid Tumors
A phase 1/2 trial of CRN09682 in neuroendocrine tumours, run by Crinetics Pharmaceuticals Inc., now recruiting.
Overview
A Study to Investigate Safety and Effectiveness of CRN09682 in Participants With SST2-Expressing NENs and Other Solid Tumors is a phase 1/2 interventional study registered as NCT07129252 by Crinetics Pharmaceuticals Inc., with 150 participants planned, started 2025-11-26 and due to reach its primary completion in 2027-08. Interventions recorded: CRN09682.
Similar pages
not linked directly; found by shared links- TrialCarcinoid Syndrome Efficacy Study Featuring an Oral Daily Paltusotine Regimen
Shares Crinetics Pharmaceuticals, Neuroendocrine tumours and the tag pipeline.
- TrialA Study to Evaluate the Safety and PK of CRN04894 for the Treatment of Cushing's Syndrome
Shares Crinetics Pharmaceuticals and the tag pipeline.
- TrialStudy of CVM-1118 for Patients With Advanced Neuroendocrine Tumors
Shares Neuroendocrine tumours and the tag pipeline.
- TrialDose-defining Study of Tirapazamine Combined With Embolization in Liver Cancer
Shares Neuroendocrine tumours and the tag pipeline.
- TrialA Phase 1/2 Study to Evaluate CHM-2101, an Autologous Cadherin 17 Chimeric Antigen Receptor (CAR) T Cell Therapy
Shares Neuroendocrine tumours and the tag pipeline.
- TrialA Phase 1/2a Study of 23ME-00610 in Patients With Advanced Solid Malignancies
Shares Neuroendocrine tumours and the tag pipeline.
- TrialDAREON™-5: A Study to Test Whether Different Doses of BI 764532 Help People With Small Cell Lung Cancer or Other Neuroendocrine Cancers
Shares Neuroendocrine tumours and the tag pipeline.
- TrialA Study Comparing Treatment With Lutetium[177Lu] Oxodotreotide Injection to Octreotide LAR in Patients With GEP-NETs
Shares Neuroendocrine tumours and the tag pipeline.